Research programme: inflammatory disease-targeted antibodies - PeptimmuneAlternative Names: DEEP-Ab
Latest Information Update: 29 Aug 2011
At a glance
- Originator Peptimmune
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Inflammation
Most Recent Events
- 22 Mar 2011 Suspended - Preclinical for Inflammation in USA (Parenteral)
- 19 Jul 2010 Preclinical trials in Inflammation in USA (Parenteral)